$166 Million is the total value of Sio Capital Management, LLC's 31 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OASMY | Exit | OASMIA PHARMACEUTICAL ABadr | $0 | – | -203,170 | -100.0% | -0.10% | – |
| STDY | Exit | STEADYMED LTD | $0 | – | -54,950 | -100.0% | -0.11% | – |
| QSII | Exit | QUALITY SYSTEMS INCput | $0 | – | -18,200 | -100.0% | -0.14% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -83,428 | -100.0% | -0.28% | – |
| PGNX | Exit | PROGENICS PHARMACEUTICALS INC | $0 | – | -83,523 | -100.0% | -0.28% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -131,200 | -100.0% | -0.44% | – |
| MYOV | Exit | MYOVANT SCIENCES LTD | $0 | – | -73,054 | -100.0% | -0.52% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -3,000 | -100.0% | -0.62% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -35,000 | -100.0% | -0.67% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -12,209 | -100.0% | -0.68% | – |
| ODT | Exit | ODONATE THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.70% | – |
| VCRA | Exit | VOCERA COMMUNICATIONS INC | $0 | – | -55,454 | -100.0% | -0.94% | – |
| NTUS | Exit | NATUS MEDICAL INCput | $0 | – | -53,000 | -100.0% | -1.14% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -14,874 | -100.0% | -1.26% | – |
| XNCR | Exit | XENCOR INC | $0 | – | -109,981 | -100.0% | -1.36% | – |
| LGND | Exit | LIGAND PHARMACEUTICALS INCcall | $0 | – | -18,000 | -100.0% | -1.39% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -19,000 | -100.0% | -1.41% | – |
| AAAP | Exit | ADVANCED ACCELERATOR APPLICATIONS SAsponsored ads | $0 | – | -32,736 | -100.0% | -1.51% | – |
| MD | Exit | MEDNAX INC | $0 | – | -56,598 | -100.0% | -1.71% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -885,055 | -100.0% | -1.94% | – |
| PFE | Exit | PFIZER INCput | $0 | – | -100,000 | -100.0% | -2.04% | – |
| HCA | Exit | HCA HEALTHCARE INCcall | $0 | – | -42,100 | -100.0% | -2.09% | – |
| EBS | Exit | EMERGENT BIOSOLUTIONS INC | $0 | – | -91,533 | -100.0% | -2.40% | – |
| UNH | Exit | UNITEDHEALTH GROUP INCcall | $0 | – | -20,000 | -100.0% | -2.49% | – |
| PINC | Exit | PREMIER INCcall | $0 | – | -160,000 | -100.0% | -2.63% | – |
| TNET | Exit | TRINET GROUP INCcall | $0 | – | -110,000 | -100.0% | -2.75% | – |
| CAH | Exit | CARDINAL HEALTH INCcall | $0 | – | -80,000 | -100.0% | -2.76% | – |
| ASGN | Exit | ON ASSIGNMENT INCcall | $0 | – | -77,000 | -100.0% | -2.79% | – |
| ISRG | Exit | INTUITIVE SURGICAL INCput | $0 | – | -16,000 | -100.0% | -3.29% | – |
| QTNT | Exit | QUOTIENT LTD | $0 | – | -1,426,125 | -100.0% | -3.98% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -325,823 | -100.0% | -6.52% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCput | $0 | – | -179,200 | -100.0% | -16.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.